Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher - Time to Buy?

Key Points

• Shares of Polaryx Therapeutics jumped 4.9% on Tuesday to $6.47 (intraday high $6.49) on light trading of 141,137 shares, about a 94% decline versus its average daily volume of ~2.27 million shares.
• Maxim Group initiated coverage with a Buy rating and a $10 price target, leaving the stock's current consensus rating and target at "Buy" and $10 (based on one analyst).
• Polaryx is a clinical-stage biotech focused on developing multimodal, disease-modifying therapies—including small molecules and gene therapy—for rare pediatric lysosomal storage disorders.

Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report) traded up 4.9% during trading on Tuesday . The company traded as high as $6.49 and last traded at $6.47. 141,137 shares were traded during trading, a decline of 94% from the average session volume of 2,268,150 shares. The stock had previously closed at $6.17.

Analyst Upgrades and Downgrades

Separately, Maxim Group started coverage on Polaryx Therapeutics in a report on Friday, February 27th. They set a "buy" rating and a $10.00 target price on the stock. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $10.00.

Polaryx Therapeutics Stock Up 4.9%

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.